Stockreport

Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval [Seeking Alpha]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF Cabozantinib remains the near-term growth driver, while zanzalintinib is positioned as the next major oncology franchise, targeting $5B in annual revenue by 2033. EXE [Read more]